The Effect of Financial and Educational Incentives on Rational Prescribing. A State-Space Approach

Health Economics (United Kingdom)

Volumn 24, Issue 4, 2015, Pages 439-453

  Pechlivanoglou, Petros ^a,b   Wieringa, Jaap E ^a   De Jager, Tim ^a   Postma, Maarten J ^a  

^a UNIVERSITY OF GRONINGEN   (Netherlands)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

drug prescribing; financial incentives; health insurers; Kalman filter; state space; the Netherlands; time series

Indexed keywords

ILLICIT DRUG; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PROTON PUMP INHIBITOR;

ADOLESCENT; ADULT; AGE; ALCOHOL CONSUMPTION; ARTICLE; DRUG ABUSE; FEMALE; HUMAN; MALE; NATIONAL LONGITUDINAL STUDY OF ADOLESCENT HEALTH; PRIORITY JOURNAL; REGRESSION ANALYSIS; CLINICAL PRACTICE; DRUG COST; ECONOMICS; EPIDEMIOLOGY; MEDICAL EDUCATION; NETHERLANDS; PROGRAM EVALUATION; PROSPECTIVE PAYMENT; STATISTICS AND NUMERICAL DATA; THEORETICAL MODEL;

DRUG COSTS; EDUCATION, MEDICAL, CONTINUING; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MODELS, THEORETICAL; NETHERLANDS; PRACTICE PATTERNS, PHYSICIANS'; PROGRAM EVALUATION; PROSPECTIVE PAYMENT SYSTEM; PROTON PUMP INHIBITORS;

EID: 84924752320     PISSN: 10579230     EISSN: 10991050     Source Type: Journal    
DOI: 10.1002/hec.3030     Document Type: Article

References (46)

1. Akaike H,. 1973. Information theory and an extension of the maximum likelihood principle. In International Symposium on Information Theory, BN Petrov, F Csaki, (eds.), Akademia Kiado: Budapest, 267-281.
2. Angrist JD, Pischke JS,. 2008. Mostly harmless econometrics: An empiricist's companion. Princeton University Press: NJ.
3. Beaulieu ND, Horrigan DR,. 2005. Putting smart money to work for quality improvement. Health Services Research 40: 1318-34.
4. Bertrand M, Duflo E, Mullainathan S,. 2004. How much should we trust difference-in-difference estimates? Quarterly Journal of Economics 119 (1): 249-275.
5. Boonen LHHM, Schut FT, Koolman X,. 2007. Consumer channelling by health insurers: natural experiments with preferred providers in the Dutch pharmacy market. Health Economics 17 (3): 299-316.
6. Boonen LHHM, van der Geest SA, Schut FT, Varkevisser M,. 2010. Pharmaceutical policy in the Netherlands: from price regulation towards managed competition. In Pharmaceutical Markets and Insurance Worldwide (Advances in Health Economics and Health Services Research, Volume 22), A Dor, (ed.), Emerald Group Publishing Limited, 53-76.
7. Bos E,. 2007. Radar verdubbelt aantal. Pharmaceutisch Weekblad 33: 12-13.
8. Comma A, Zara C, Godman B, Augusti A, Diogene E, et al,. 2009. Policies to enhance the efficiency of prescribing in the Spanish Catalan Region: impact and future direction. Expert Reviews in Pharmacoeconomics and Outcomes Research 9: 569-581.
9. Commandeur JJF, Koopman SJ,. 2007. An Introduction to State Space Time Series Analysis. Oxford University Press: Oxford.
10. Cromwell J, Trisolini MG, Pope GC, Mitchell JB, Greenwald LM,. 2011. Pay for Performance in Health Care: Methods and Approaches. RTI Press publication No. BK-0002-1103. RTI Press: Research Triangle Park, NC.
11. Davis DA, Thomson MA, Oxman AD, Haynes RB,. 1995. Changing physician performance a systematic review of the effect of continuing medical education strategies. JAMA 274 (9): 700-705.
12. Durbin J, Koopman SJ,. 2001. Time Series Analysis by State Space Methods. Oxford University Press: Ofxord.
13. Flodgren G, Eccles MP, Shepperd S, Scott A, Parmelli E, et al,. 2011. An overview of reviews evaluating the effectiveness of financial incentives in changing healthcare professional behaviours and patient outcomes. Cochrane Database System Review; 7: CD009255, 1-94.
14. Fuhrmans V,. 2008: Doctors paid to prescribe generic pills, Wall Street Journal. (Eastern edition), B (24 Jan): 1.
15. Glasziou PP, Buchan H, Del Mar C, Doust J, Harris M, et al,. 2012. When financial incentives do more good than harm: a checklist. BMJ 345: e5047, 1-5.
16. Godman B, Shrank W, Andersen M, Berg C, Bishop I, et al,. 2010. Comparing policies to enhance prescribing efficiency in Europe through increasing generic utilization: changes seen and global implications. Expert Reviews in Pharmacoeconomics and Outcomes Research 10: 707-722.
17. Godman B, Shrank W, Andersen M, Berg C, Bishop I, et al,. 2011. Policies to enhance prescribing efficiency in Europe: findings and future implications. Expert Reviews in Pharmacoeconomics and Outcomes Research 1: 1-16.
18. Greene WH,. 2002. Econometric analysis. Englewood Cliffs, Prentice Hall.
19. Griens AMGF, Tinke JL, van der Vaart RJ, 2008. Facts and Figs. 2008. Foundation for Pharmaceutical Statistics, The Hague.
20. Grimshaw JM, Thomas RE, MacLennan G, Fraser C, Ramsay CR, et al,. 2004. Effectiveness and efficiency of guideline dissemination and implementation strategies. Health Technology Assessment 8 (6): 1-72.
21. Harvey AC,. 1989. Forecasting, structural time series models and the Kalman filter. Cambridge University Press: New York
22. Headrick LA, Speroff T, Pelecanos HI, Cebul RD,. 1992. Efforts to improve compliance with the National Cholesterol Education Program guidelines. Results of a randomized controlled trial. Archives of Internal Medicine 152 (12): 2490-2496.
23. Helske J,. 2011. KFAS: Kalman filter and smoothers for exponential family state space models. R package version 0.6.1. http://CRAN.R-project.org/package=KFAS [15 February 2012]
24. Hogerzeil HV,. 1995. Promoting rational prescribing: an international perspective. British Journal of Clinical Pharmacology 39: 1-6.
25. iBMG/ Erasmus. 2007. Samenvatting evaluatie Proeftuin Farmacie Groningen (trans: Summary Evaluation of Proeftuin Farmacie Groningen). iBMG: Rotterdam.
26. Keller H, Kornes T, Becker A, et al,. 2011. Arriba: effects of an educational intervention on prescribing behaviour in prevention of CVD in general practice. European Journal of Cardiovascular Prevention and Rehabilitation 19 (3): 322-329.
27. Koopman SJ,. 1997. Exact initial Kalman filtering and smoothing for nonstationary time series models. Journal of the American Statistical Association 92 (440): 1630-1638.
28. Leeflang PSH, Wieringa JE,. 2010. Modeling the effects of pharmaceutical marketing. Marketing Letters 21: 121-133.
29. Maddala GS, Kim IM,. 1998. Unit Roots, Cointegration and Structural Change. Cambridge University Press: Cambridge.
30. Martens JD, Werkhoven MJ, Severens JL, Winkens RA,. 2007. Effects of a behaviour independent financial incentive on prescribing behaviour of general practitioners. Journal of Evaluation in Clinical Practice 13 (3): 369-373.
31. Martens JD, Winkens RA, van der Weijden T, de Bruyn D, Severens JL,. 2006. Does a joint development and dissemination of multidisciplinary guidelines improve prescribing behaviour: a pre/post study with concurrent control group and a randomised trial. BMC Health Services Research 6: 145.
32. McDonagh MS, Carson S,. 2005. Drug class review on proton pump inhibitors. Final report. Oregon Health & Science University, Portland, Ore.
33. Medves J, Godfrey C, Turner C, Paterson M, Harrison M, MacKenzie L, Durando P,. 2010. Systematic review of practice guideline dissemination and implementation strategies for healthcare teams and team-based practice. International Journal of Evidence-Based Healthcare 8 (2): 79-89.
34. Ohlsson H, Vervloet M, van Dijk L,. 2011. Practice variation in a longitudinal perspective: a multilevel analysis of the prescription of simvastatin in general practices between 2003 and 2009. European Journal of Clinical Pharmacology 67: 1205-1211.
35. Osinga EC, Leeflang PSH, Wieringa JE,. 2010. Early marketing matters: a time-varying parameter approach to persistence modeling. Journal of Marketing Research 47 (1): 173-185.
36. Ostini R, Hegney D, Jackson C, Williamson M, Mackson J, Gurman K, Hall W, Tett S,. 2009. Systematic review of interventions to improve prescribing. Annals of Pharmacotherapy 43 (3): 502-513.
37. Pechlivanoglou P, van der Veen WJ, Bos JH, Postma MJ,. 2011. Analyzing generic and branded substitution patterns in the Netherlands using prescription data. BMC Health Services Research 11 (89): 1-9.
38. R Development Core Team. 2010. R: a language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. ISBN 3-900051-07-0.
39. Serumanga B, Ross-Degnan D, Avery AJ, Elliott RA, Majumdar SR, et al,. 2011. Effect of pay-for-performance on the management and outcomes of hypertension in the United Kingdom: interrupted time-series study. BMJ 342: d108, 1-7.
40. Sheldon T,. 2006. Dutch insurance company is allowed to pay doctors bonuses to prescribe cheap drugs. British Medical Journal 332: 254.
41. Stathopoulos A, Karlaftis MG,. 2003 A multivariate state space approach for urban traffic flow modeling and prediction. Transportation Research Part C 11: 121-135.
42. Sturm H, Austvoll-Dahigren A, Aaserud M, Oxman AD, Ramsay CR, et al,. 2007. Pharmaceutical policies: effects of financial incentives for prescribers. Cochrane Database of Systematic Reviews 3 Art. No.: CD006731. DOI: 10.1002/14651858.CD006731.
43. Thomson S, Mossialos E,. 2010. Primary Care and Prescription Drugs: Coverage, Cost-Sharing, and Financial Protection in Six European Countries, The Commonwealth Fund.
44. Vakil N, Fennerty MB,. 2003. Direct comparative trials of the efficacy of proton pump inhibitors in the management of gastro-oesophageal reflux disease and peptic ulcer disease. Alimentary Pharmacology and Therapeutics 18: 559-568.
45. Weng TC, Yang YH, Lin SJ, Tai SH,. 2010. A systematic review and meta-analysis on the therapeutic equivalence of statins. Journal of Clinical Pharmacy and Therapeutics 35: 139-151.
46. Zivot E, Andrews DW, 1992. Further evidence on the great crash, the oil-price shock, and the unit-root hypothesis. Journal of Business & Economic Statistics 10 (3): 251-270